BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cariprazine: Phase II data

Top-line data from an exploratory, double-blind, U.S. Phase II trial in 233 patients showed that low- and high-dose daily oral cariprazine each missed the primary endpoint of significantly improving MADRS scores from baseline to week 8 vs. placebo. However, Forest and Gedeon Richter said there was evidence of a "clinically...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >